Stellar Biotechnologies announced that Michael Kennedy has joined the company to lead the company’s manufacturing activities.

Kennedy, who has extensive bioprocessing experience over the last 26 years related to advancing biopharmaceutical products from clinical to commercial manufacturing, will manage the company’s optimization and scale-up activities, and oversee manufacturing and purification processes at Stellar’s California manufacturing facility, which operates under current Good Manufacturing Practices (cGMP).

“Michael is an excellent addition to our manufacturing team. His experience in process optimization, new facility engineering and quality system implementation will further enhance Stellar’s ability to expand production of GMP grade KLH for the immunotherapy and diagnostic markets,” said Gregory T. Baxter, PhD, Stellar executive vice president of Corporate Development.

Prior to joining Stellar, Kennedy led manufacturing teams and process engineering at Shire, Inc., Symex and Amgen, Inc.